Compare Novo Nordisk A/S (NVO) vs Energy Select Sector SPDR Fund (XLE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Energy Select Sector SPDR Fund — how do they compare? Novo Nordisk A/S trades at $38.64 (market cap $165.31B), while Energy Select Sector SPDR Fund trades at $65.09 (market cap $40.84B). The key difference: Novo Nordisk A/S is far larger — about 4× Energy Select Sector SPDR Fund's market cap, and Novo Nordisk A/S pays a 4.71% dividend while Energy Select Sector SPDR Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Energy Select Sector SPDR Fund for 67 Days on average.
| NVO | XLE | |
|---|---|---|
Market Cap | $165.31B | $40.84B |
Volume | 11,432,838 | 50,409,268 |
Sector | Health | — |
52-Week High | $63.98 | $65.93 |
52-Week Low | $35.29 | $42.61 |
Typical Hold Time | 116 Days | 67 Days |
Enterprise Value | $179.56B | — |
Dividend Yield | 4.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.18, down 0.21% with a bearish technical signal. The stock shows strong fundamentals with a P/E of 9.66, net margin of 35.35%, and consistent earnings beats. Recent news highlights pipeline developments including Wegovy pill data and a $4 billion licensing deal expansion. Cash flow remains positive at $10.81B despite increased capital expenditures.
The outlook remains positive with 59% analyst buy ratings and a $44.67 price target representing 17% upside. Key risks include FDA delays for hemophilia drug denecimig and intensifying competition from Eli Lilly. Revenue growth continues at 6.6% annually with improving profitability margins supporting valuation expansion potential.
XLE trades at $65.24, up 2.93% with a bullish technical signal from moving averages, though oscillators show caution with RSI readings above 70. The energy ETF faces mixed sentiment amid geopolitical tensions and oil price volatility, with recent news highlighting both supply risks and potential price reversals. Key support sits at $64-65 while resistance levels cluster around $66.
Outlook remains tied to oil market dynamics with Middle East tensions and Fed policy as key drivers. Investment opportunity exists for energy exposure, but risks include oil price collapse and sector rotation. The ETF's 91% oil and gas concentration amplifies commodity price sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Energy Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as energy companies by the GICS®, including securities of companies from the following industries: oil, gas and consumable fuels; and energy equipment and services. It is non-diversified.
Read more on XLE →
